Параллели между неалкогольной жировой болезнью печени и неалкогольной жировой болезнью поджелудочной железы: в поисках точек соприкосновения или взгляд сквозь призму метаболического синдрома

Цель исследования. Целью нашего исследования было проанализировать имеющиеся данные литературных источников, касающиеся вопросов этиологии, патогенеза, клиники, диагностики, а также особенностей лечения неалкогольной жировой болезни печени (НАЖБП) и неалкогольной жировой болезни поджелудочной железы (НАЖБПЖ).

Материалы и методы. Нами проведен ретроспективный анализ зарубежных источников литературы, содержащих актуальную современную информацию о состоянии проблемы НАЖБП и НАЖБПЖ.

Результаты. НАЖБП и НАЖБПЖ развиваются на фоне метаболического синдрома (МС), системной инсулинорезистентности, окислительного стресса, изменения метаболизма липидов. Естественное течение НАЖБПЖ ассоциировано с высоким риском прогрессирования МС, возникновения НАЖБП, артериальной гипертонии, сахарного диабета 2-го типа, внешнесекреторной недостаточности поджелудочной железы (ПЖ), острого и хронического панкреатита, рака ПЖ. Коррекция компонентов МС позволяет уменьшить выраженность НАЖБП и НАЖБПЖ; проведение заместительной ферментной терапии способно улучшить функцию β-клеток при стеатозе ПЖ.

Заключение. Возможности фармакологического лечения НАЖБП и НАЖБПЖ продолжают активно изучаться. Мы подчеркиваем целесообразность включения в схемы лечения НАЖБПЖ препаратов, содержащих ферменты ПЖ.

1. Губергриц Н. Б., Беляева Н. В., Лукашевич Г. М. и соавт. Доказательная панкреатология: что мы знаем о хроническом панкреатите к 2020 году?// Сучасна гастроентерологія, 2020, № 3, С. 96–110. https://doi.org/10.30978/MG-2020–3–96

2. Стародубова А. В., Косюра С. Д., Ливанцова Е. Н. и соавт. Диагностика стеатоза поджелудочной железы у лиц с ожирением// Вестник клуба панкреатологов, 2019, № 4, С. 30–33.

3. Acharya C., Navina S., Singh V. P. Role of pancreatic fat in the outcomes of pancreatitis. Pancreatology, 2014, vol. 14, no. 5, pp. 403–408. doi:10.1016/j.pan.2014.06.004

4. Adams L.A., Anstee Q. M., Tilg H. et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, no. 66, pp. 1138–53. doi:10.1136/gutjnl-2017–313884

5. Alempijevic T., Dragasevic S., Zec S. et al. Nonalcoholic fatty pancreas disease. Postgrad Med J, 2017, vol. 93, no. 1098, pp. 226–230. doi:10.1136/postgradmedj-2016–134546

6. Beger H.G., editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery, Oxford: Willey Blackwell, 2018, 1173 p.

7. Bi Y., Wang J. L., Li M. L. et al. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2019, vol. 35, no. 5, e3142. doi:10.1002/dmrr.3142

8. Birkenfeld A.L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology, 2014, no. 59, pp. 713–23. doi:10.1002/hep.26672

9. Brown J.M., Hazen S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med, 2015, no. 66, pp. 343–59. doi:10.1146/annurev-med-060513–093205

10. Brunner K.T., Pedley A., Massaro J. M. et al. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int, 2020, vol. 40, no. 6, pp. 1339–1343. doi:10.1111/liv.14472.

11. Capurso G., Traini M., Piciucchi M. et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol, 2019, no. 12, pp. 129–139. doi:10.2147/CEG.S168266

12. Catanzaro R., Cuffari B., Italia A. et al. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol, 2016, vol. 22, no. 34, pp. 7660–7675. doi:10.3748/wjg.v22.i34.7660

13. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, no. 67, pp. 328–57. doi:10.1002/hep.29367

14. Chiyanika C., Chan D. F., Hui S. C. et al. The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease. Pediatr Obes, 2020, e12653. doi:10.1111/ijpo.12653

15. Corey K.E., Misdraji J., Gelrud L. et al. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profi le. Lipids Health Dis, 2014, no. 13, p. 100. doi:10.1186/1476–511X-13–100

16. Coulon S., Francque S., Colle I. et al. Evaluation of infl ammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine, 2012, no. 59, pp. 442–9. doi:10.1016/j.cyto.2012.05.001

17. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 2012, no. 142, pp. 711–25.e6. doi:10.1053/j.gastro.2012.02.003

18. DeFilippis A.P., Blaha M. J., Martin S. S. et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013, no. 227, pp. 429–36. doi:10.1016/j.atherosclerosis.2013.01.022

19. Dite P., Blaho M., Bojkova M. et al. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. Dig Dis, 2020, vol. 38, no. 2, pp. 143–149. doi:10.1159/000505366

20. Dominguez-Munoz J.E., Drewes A. M., Lindkvist B. et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis [published correction appears in Pancreatology. 2020 Jan;20(1):148]. Pancreatology, 2018, vol. 18, no. 8, pp. 847–854. doi:10.1016/j.pan.2018.09.016

21. El Hadi H., Di Vincenzo A., Vettor R. et al. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells, 2020, vol. 9, no. 3, 567 p. doi:10.3390/cells9030567

22. Emre A., Terzi S., Celiker E. et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol, 2015, no. 116, pp. 1810–4. doi:10.1016/j.amjcard.2015.09.021

23. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, no. 64, pp. 1388–402. doi:10.1007/s00125–016–3902-y

24. Ferrara D., Montecucco F., Dallegri F. et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol, 2019, vol. 234, no. 12, pp. 21630–21641. doi:10.1002/jcp.28821

25. Francque S., Laleman W., Verbeke L. et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest, 2012, no. 92, pp. 1428–39. doi:10.1038/labinvest.2012.103

26. Francque S.M., van der Graaff D., Kwanten W. J. Nonalcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol, 2016, no. 65, pp. 425–43. doi:10.1016/j.jhep.2016.04.005

27. Fraser A., Harris R., Sattar N. et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care, 2009, no. 32, p. 741–50. doi:10.2337/dc08–1870

28. Fujii M., Ohno Y., Yamada M. et al. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. Environ Health Prev Med, 2019, vol. 24, no. 1, pp. 10–12. doi:10.1186/s12199–019–0763–2

29. Gaborit B., Abdesselam I., Kober F. et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes (Lond), 2015, vol. 39, no. 3, pp. 480–487. doi:10.1038/ijo.2014.126

30. Gardner T.B., Adler D. G., Forsmark C. E. et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol, 2020, vol. 115, no. 3, pp. 322–339. doi:10.14309/ajg.0000000000000535

31. Gerst F., Wagner R., Oquendo M. B. et al. What role do fat cells play in pancreatic tissue? Mol Metab, 2019, no. 25, pp. 1–10. doi:10.1016/j.molmet.2019.05.001

32. Gill R.M., Belt P., Wilson L. et al. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol, 2011, no. 35, pp. 1400–4. doi:10.1097/PAS.0b013e3182254283

33. Guo K., Zhang L., Lu J. et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications, 2017, no. 31, pp. 80–5. doi:10.1016/j.jdiacomp.2016.09.008

34. Hallsworth K., Hollingsworth K. G., Thoma C. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol, 2013, no. 58, pp. 757–62. doi:10.1016/j.jhep.2012.11.015

35. Heiskanen M.A., Motiani K. K., Mari A. et al. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial. Diabetologia, 2018, vol. 61, no. 8, pp. 1817–1828. doi:10.1007/s00125–018–4627-x

36. Honka H., Koffert J., Hannukainen J. et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab, 2015, vol. 100, no. 5, pp. 2015–2023. doi:10.1210/jc.2014–4236

37. Huang C.T., Lin C. K., Lee T. et al. Pancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications. Diagnostics (Basel), 2020, vol. 10, no. 2, E87. doi:10.3390/diagnostics10020087

38. Jaruvongvanich V., Wirunsawanya K., Sanguankeo A. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis, 2016, no. 48, pp. 1410–7. doi:10.1016/j.dld.2016.09.002

39. Kang J.H., Cho K. I., Kim S. et al. Relationship between nonalcoholic fatty liver disease and carotid artery atherosclerosis beyond metabolic disorders in non-diabetic patients. J Cardiovasc Ultrasound, 2012, no. 20, pp. 126–33. doi:10.4250/jcu.2012.20.3.126

40. Kasumov T., Edmison J. M., Dasarathy S. et al. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism, 2011, no. 60, pp. 776–81. doi:10.1016/j.metabol.2010.07.027

41. Keskin M., Hayiroglu M. I., Uzun A. O. et al. Effect of nonalcoholic fatty liver disease on in-hospital and longterm outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol, 2017, no. 120, pp. 1720–6. doi:10.1016/j.amjcard.2017.07.107

42. Ketwaroo G.A., Graham D. Y. Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain. Adv Exp Med Biol, 2019, no. 1148, pp. 323–343. doi:10.1007/978–981–13–7709–9_14

43. Kim J., Lee D. Y., Park S. et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic infl ammation. PLoS One, 2017, no. 12, e0180118. doi:10.1371/journal.pone.0180118

44. Kumar R., Priyadarshi R. N., Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol, 2020, vol. 8, no. 1, pp. 76–86. doi:10.14218/JCTH.2019.00051

45. Lazar M.V., Eapen M., Nair H. R. et al. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity. Indian J Gastroenterol, 2020, vol. 39, no. 1, pp. 42–49. doi:10.1007/s12664–020–01024-z.

46. Leamy A.K., Egnatchik R. A., Young J. D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res, 2013, no. 52, pp. 165–74. doi:10.1016/j.plipres.2012.10.004

47. Lesmana C.R., Pakasi L. S., Inggriani S. et al. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMC Gastroenterol, 2015, no. 15, pp. 174–7. doi:10.1186/s12876–015–0404–1

48. Lesmana C., Gani R. A., Lesmana L. A. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. JGH Open, 2017, vol. 2, no. 1, pp. 4–7. doi:10.1002/jgh3.12032

49. Ma J., Hwang S. J., Pedley A. et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, no. 66, pp. 390–7. doi:10.1016/j.jhep.2016.09.022

50. Mahfood Haddad T., Hamdeh S., Kanmanthareddy A. et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, S209–16. doi:10.1016/j.dsx.2016.12.033

51. Majumder S., Philip N. A., Takahashi N. et al. Fatty Pancreas: Should We Be Concerned? Pancreas, 2017, vol. 46, no. 10), pp. 1251–1258. doi:10.1097/MPA.0000000000000941

52. Mandai K., Uno K., Nakase K. et al. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms. J Med Ultrason, 2019, vol. 46, no. 4, pp. 435–439. doi:10.1007/s10396–019–00949-z

53. Mannisto V.T., Simonen M., Soininen P. et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res, 2014, no. 55, pp. 2676–84. doi:10.1194/jlr.P054387

54. Mantovani A., Byrne C. D., Bonora E. et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care, 2018, no. 41, pp. 372–82. doi:10.2337/dc17–1902

55. Milovanovic T., Dragasevic S., Stojkovic Lalosevic M. et al. Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease-A Cross Sectional Study. Medicina (Kaunas), 2019, vol. 55, no. 10, pp. 697–8. doi:10.3390/medicina55100697

56. Nghiem D.D., Olson P. R., Ormond D. The “fatty pancreas allograft”: anatomo-pathologic fi ndings and clinical experience. Transplant Proc, 2004, vol. 36, no. 4, pp. 1045–1047. doi:10.1016/j.transproceed.2004.04.032

57. Niederseer D., Wernly S., Bachmayer S. et al. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med, 2020, vol. 9, no. 4, pp. 1065–6. doi:10.3390/jcm9041065

58. Pacana T., Cazanave S., Verdianelli A. et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One, 2015, vol. 10, no. 8, e0136822. doi:10.1371/journal.pone.0136822.

59. Pickhardt P.J., Hahn L., Munoz del Rio A. et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. Am J Roentgenology, 2014, no. 202, pp. 752–8. doi:10.2214/AJR.13.11367

60. Pinnick K.E., Collins S. C.., Londos C et al. Pancreatic ectopic fat is characterized by adipocyte infi ltration and altered lipid composition. Obesity (Silver Spring), 2008, vol. 16, no. 3, pp. 522–530. doi:10.1038/oby.2007.110

61. Pinte L., Balaban D. V., Băicuş C. et al. Non-alcoholic fatty pancreas disease – practices for clinicians. Rom J Intern Med, 2019, vol. 57, no. 3, pp. 209–219. doi:10.2478/rjim-2019–0005

62. Pisto P., Santaniemi M., Bloigu R. et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 2014, vol. 4, no. 3, e004973. doi:10.1136/bmjopen-2014–004973

63. Prachayakul V., Aswakul. P. Pancreatic Steatosis: What Should Gastroenterologists Know? JOP, 2015, vol 16, no. 3, pp. 227–231.

64. Puchner SB, Lu MT, Mayrhofer T, et al. Highrisk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015, no. 274, pp. 693–701. doi:10.1148/radiol.14140933

65. Puri P., Sanyal A. J. Nonalcoholic fatty liver disease: Defi nitions, risk factors, and workup. Clin Liver Dis (Hoboken), 2012, vol. 1, no. 4, pp. 99‐103. doi:10.1002/cld.81

66. Ramkissoon R., Gardner T. B. Pancreatic Steatosis: An Emerging Clinical Entity. Am J Gastroenterol, 2019, vol. 114, no. 11, pp. 1726–1734. doi:10.14309/ajg.0000000000000262

67. Romana B.S., Chela H., Dailey F. et al. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review. Endocr Metab Immune Disord Drug Targets, 2018, vol. 18, no. 6, pp. 547–554. doi:10.2174/1871530318666180328111302

68. Sabag A., Way K. L., Keating S. et al. Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab, 2017, vol. 43, no. 3, pp. 195–210. doi:10.1016/j.diabet.2016.12.006

69. Sakai N.S., Taylor S. A., Chouhan M. D. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. Br J Radiol, 2018, vol. 91, no. 1089, pp. 2018–67. doi:10.1259/bjr.20180267

70. Shah N., Rocha J.P, Bhutiani N. et al. Nonalcoholic Fatty Pancreas Disease. Nutr Clin Pract, 2019, vol. 34, no. 1, pp. S49–S56. doi:10.1002/ncp.10397

71. Shobassy M., Husainat N., Tabash A. et al. Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterol Res Pract, 2019, no. 2019, pp. 5290642. doi:10.1155/2019/5290642

72. Siddiqui M.S., Fuchs M., Idowu M. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profi le. Clin Gastroenterol Hepatol, 2015, no. 13, pp. 1000–8.e3. doi:10.1016/j.cgh.2014.10.008

73. Singh R.G., Yoon H. D., Poppitt S. et al. Ectopic fat accumulation in the pancreas and its biomarkers: A systematic review and meta-analysis. Diabetes Metab Res Rev, 2017, vol. 33, no. 8, pp. 10–11.1002/dmrr.2918. doi:10.1002/dmrr.2918

74. Singh R.G., Yoon H. D., Wu L. et al. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism, 2017, no. 69, pp. 1–13. doi:10.1016/j.metabol.2016.12.012

75. Sinn D.H., Kang D., Chang Y. et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, no. 66, pp. 323–9. doi:10.1136/gutjnl-2016–311854

76. Skurk T., Alberti-Huber C., Herder C. et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 2007, vol. 92, no. 3, pp. 1023–1033. doi:10.1210/jc.2006–1055

77. Smereczyński A., Kołaczyk K. Is a fatty pancreas a banal lesion? J Ultrason, 2016, vol. 16, no. 66, pp. 273–280. doi:10.15557/JoU.2016.0027

78. Smits M.M., van Geenen E. The clinical significance of pancreatic steatosis. Nat. Rev. Gastroenterol. Hepatol., 2011, no. 8, pp. 169–77. doi:10.1038/nrgastro.2011.4

79. Sonmez A., Nikolic D., Dogru T. et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol, 2015, no. 9, pp. 576–82. doi:10.1016/j.jacl.2015.03.010

80. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol, 2008, no. 49, pp. 600–7. doi:10.1016/j.jhep.2008.06.012

81. Souza-Mello V., Gregório B. M., Cardoso-de-Lemos F. et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond), 2010, vol. 119, no. 6, pp. 239–250. doi:10.1042/CS20100061

82. Sperling L.S., Mechanick J. I., Neeland I. et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol, 2015, no. 66, pp. 1050–67. doi:10.1016/j.jacc.2015.06.1328

83. Sreedhar U.L., DeSouza S.V., Park B. et al. A Systematic Review of Intra-pancreatic Fat Deposition and Pancreatic Carcinogenesis. J Gastrointest Surg, 2019, 10.1007/s11605–019–04417–4. doi:10.1007/s11605–019–04417–4

84. Stahl E.P., Dhindsa D. S., Lee S. et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019, vol. 73, no. 8, pp. 948–963. doi:10.1016/j.jacc.2018.11.050

85. Sujishi T., Fukunishi S., Ii M. et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. J Clin Biochem Nutr, 2015, vol. 57, no. 3, pp. 244–253. doi:10.3164/jcbn.15–84

86. Tahtac M., Algın O., Karakan T. et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk J Gastroenterol, 2018, vol. 29, no. 5, pp. 588–594. doi:10.5152/tjg.2018.17696

87. Targher G., Byrne C. D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol, 2016, no. 65, pp. 589–600. doi:10.1016/j.jhep.2016.05.013

88. Tirkes T., Jeon C..Y, Li L. et al. Association of Pancreatic Steatosis With Chronic Pancreatitis, Obesity, and Type 2 Diabetes Mellitus. Pancreas, 2019, vol. 48, no. 3, pp. 420–426. doi:10.1097/MPA.0000000000001252

89. Tomita Y., Azuma K., Nonaka Y. et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas, 2014, vol. 43, no. 7, pp. 1032–1041. doi: 10.1097/MPA.0000000000000159.

90. Treeprasertsuk S., Leverage S., Adams L. et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int, 2012, no. 32, pp. 945–50. doi:10.1002/hep4.1391

91. Tripodi A., Fracanzani A. L., Primignani M. et al. Procoagulant imbalance in patients with nonalcoholic fatty liver disease. J Hepatol, 2014, no. 61, pp. 148–54. doi:10.1016/j.jhep.2016.09.025

92. Tsatsoulis A., Mantzaris M. D., Bellou S. et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment – an evolutionary perspective. Metabolism, 2013, vol 62, no. 5, pp. 622–633. doi:10.1016/j.metabol.2012.11.004

93. Uygun A., Kadayifci A., Demirci H. et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med, 2015, vol. 26, no. 1, pp. 37–41. doi:10.1016/j.ejim.2014.11.007

94. van Raalte D. H., van der Zijl N. J., Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care, 2010, vol. 13, no. 4, pp.:478–485. doi:10.1097/MCO.0b013e32833aa1ef

95. VanWagner L.B., Wilcox J. E., Colangelo L. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology, 2015, no. 62, pp. 773–83. doi:10.1002/hep.27869

96. Vege S.S., Gardner T. B., Chari ST. et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis.” Am J Gastroenterol, 2009, no. 104, pp. 710–715. doi:10.1038/ajg.2008.77

97. Virtue S., Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol, 2008, vol. 6, no. 9, e237. doi:10.1371/journal.pbio.0060237

98. Weng S., Zhou J., Chen X. et al. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore), 2018, vol. 97, no. 26, e11293. doi:10.1097/MD.0000000000011293

99. Whitcomb D. C. Clinical practice. Acute pancreatitis. N Engl J Med, 2006, no. 354, pp. 2142–2150. doi:10.1056/NEJMcp054958

100. Wong V.W., Wong G. L., Yeung J. C. et al. Longterm clinical outcomes aft er fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology, 2016, no. 63, pp. 754–63. doi:10.1002/hep.28253

101. Wu R., Hou F., Wang X. et al. Nonalcoholic fatty liver disease and coronary artery calcification in a northern chinese population: a cross sectional study. Sci Rep, 2017, no. 7, pp. 9933–4. doi:10.1038/s41598–017–09851–5

102. Younossi Z., Anstee Q. M., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, no. 15, pp. 11–20. doi:10.1038/nrgastro.2017.109

103. Yu T., Wang C. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. J Diabetes Investig, 2017, no. 8, pp. 735–747. doi:10.1111/jdi.12665

104. Zhou J., Li M. L., Zhang D. et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology, 2016, vol. 16, no. 4, pp. 578–583. doi:10.1016/j.pan.2016.03.008

105. Zhou Y.Y., Zhou X. D., Wu S. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and metaanalysis. Hepatology Communications, 2018, vol. 2, no. 4, pp. 376–392. doi:10.1002/hep4.1155

106. Zsóri G., Illés D., Ivány E. et al. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord, 2019, vol. 17, no. 5, pp. 289–295. doi:10.1089/met.2018.0086

107. Zyromski N.J., White P. B. Pancreatic cancer in obesity: epidemiology, clinical observations, and basic mechanisms. Anticancer Agents Med Chem, 2011, vol. 11, no. 5, pp. 470–478. doi:10.2174/187152011795677445